Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flt3 Ligand With or Without Melanoma Peptide Immunization in Metastatic Melanoma or Renal Cell Cancer
NCT00019396Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 1998
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of Flt3 ligand in melanoma, renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Feb 1998; status: completed.
02
Drugs
Flt3 ligand
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00019396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019396.